Cooley and Wilson Sonsini Goodrich & Rosati have advised Candid Therapeutics. Covington & Burling has represented UCB. UCB, a global biopharmaceutical company, has announced a definitive...
UCB to Acquire Candid Therapeutics in $2.2 Billion Deal
UCB Acquires Neurona Therapeutics in $1.15 Billion Deal
Covington has advised UCB. Wilson Sonsini Goodrich & Rosati has advised Neurona Therapeutics. UCB, a global biopharmaceutical company, has entered into a definitive agreement to acquire...
Bristol Myers Squibb to Acquire Orbital Therapeutics in $1.5 Billion Agreement
Covington & Burling LLP has advised Bristol Myers Squibb, and Goodwin Proctor LLP has advised Orbital Therapeutics. Bristol Myers Squibb has entered into a definitive agreement...
IGI Therapeutics Enters Exclusive Global Licensing Agreement with AbbVie
Covington has advised IGI Therapeutics on the transaction. IGI Therapeutics SA, a wholly owned subsidiary of Ichnos Glenmark Innovation, Inc. (IGI), has entered into an exclusive...
Bristol Myers Squibb’s $286 Million Acquisition of 2seventy bio
Covington & Burling advised Bristol Myers Squibb on the deal, and Goodwin Procter advised 2seventy bio. Bristol Myers Squibb (NYSE: BMY) (“BMS”) announced its merger agreement...
Lantheus’ $750 Million Acquisition of Life Molecular Imaging
Covington & Burling advised Lantheus Holdings, Inc. on the deal. Lantheus Holdings, Inc. (Nasdaq: LNTH) (Lantheus) announced its definitive agreement to acquire Life Molecular Imaging Limited,...
Merck’s $1.3 Billion Acquisition of Elanco’s Aqua Business
Covington & Burling is advising Merck Animal Health on the transaction, and White & Case is advising Elanco Animal Health Inc. Merck Animal Health (Merck)(NYSE: MRK) announced...
Ascend Gene & Cell Therapies’ $130 Million Series A Fundraise
Covington advised lead investors Abingworth and other syndicate members on the round. Ascend closed its $130 million Series A fundraise. Ascend will use the proceeds to launch...